GABRQ
ENSG00000268089
Target class
Ion channel
Chromosome
X
Approved drugs
55
Clinical candidates (approved and in development)
66
- Approved drugs
- 55
- Clinical candidates (approved and in development)
- 66
- Chemical probe available
- No
- Target name
- GABRQ
- Gene name
- Gamma-aminobutyric acid type A receptor subunit theta
- Gene symbol
- GABRQ
- Protein name
- Gamma-aminobutyric acid receptor subunit theta (GABA(A) receptor subunit theta) (GABAAR subunit theta)
- Gene biotype
- Protein coding
- Gene family
- Gamma-aminobutyric acid type A receptor subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 11
- Highest tissue expression
- 15.56
- Tissue specificity (Gini)
- 0.808
- Tissue specificity (tau)
- 0.961
- KEGG gene identifiers
- hsa:55879
- Protein interaction confidence
- 0.808385
- Protein interaction partners
- 13
- R-HSA-1236394
- R-HSA-977443
- End position
- 152657542
- Start position
- 152637895
- Chromosome
- X
- Strand
- Forward
- Postsynaptic cell membrane
- Multi-pass membrane protein . Cell membrane
- Multi-pass membrane protein .
- Tissue specificity (tau)
- 0.960797
- Expression inequality (Gini)
- 0.807897
Expression in transcripts per million
- Brain - Hypothalamus
- 15.56
- Cervix - Endocervix
- 4.66
- Cervix - Ectocervix
- 3.47
- Nerve - Tibial
- 3.17
- Brain - Anterior cingulate cortex (BA24)
- 2.9
Expression in transcripts per million
- Brain - Hypothalamus15.56
- Cervix - Endocervix4.66
- Cervix - Ectocervix3.47
- Nerve - Tibial3.17
- Brain - Anterior cingulate cortex (BA24)2.9
- Brain - Hippocampus2.65
- Brain - Amygdala2.6
- Brain - Nucleus accumbens (basal ganglia)2.16
- Testis1.85
- Brain - Frontal Cortex (BA9)1.13
- Vagina1.03
- Esophagus - Mucosa0.94
- Brain - Cortex0.91
- Brain - Spinal cord (cervical c-1)0.78
- Brain - Caudate (basal ganglia)0.65
- Brain - Substantia nigra0.58
- Brain - Putamen (basal ganglia)0.41
- Prostate0.31
- Brain - Cerebellum0.23
- Brain - Cerebellar Hemisphere0.23
- Uterus0.2
- Skin - Not Sun Exposed (Suprapubic)0.2
- Fallopian Tube0.19
- Skin - Sun Exposed (Lower leg)0.18
- Pituitary0.18
And 29 more, listed on the interactive page.
Biological processes
- GO:0007165
- GO:0005886
- GO:0043235
- GO:0004888
- GO:0004890
- GO:0005326
- GO:0005515
- GO:0022851
Related records
Trials (3,869)
- "Chou's Tiaoshen" Acupoints for Short-term Insomnia.
- "Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail
- (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
- 1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia
- 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
- 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)
- 3 mL Inhaled Methoxyflurane for Intrauterine Device (IUD) Insertion
- 50% Effective Concentration of Sevoflurane for Immobility
- 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A Better Choice for Patients Undergoing Endovascular Coil Embolization
- A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
- A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Evaluating Sedation of Intravenous Administration of HSK3486 in ICU Patients Undergoing Long-Term Mechanical Ventilation
- A Clinical Study of Remimazolam Tosilate Compared to Propofol for General Anesthesia During Elective Surgery
- A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- A Clinical Study to Determine the Safety, Tolerability and Effect of RLS-0071 Doses When Given to Healthy Adults After Inhaling LPS
Drugs (76)
- ABP-700 GABA-A receptor; anion channel agonist
- Acamprosate GABA-A receptor; anion channel positive modulator
- Acamprosate calcium GABA-A receptor; anion channel positive modulator
- Adipiplon GABA-A receptor; anion channel partial agonist
- Alprazolam GABA-A receptor; anion channel positive allosteric modulator
- Brexanolone GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital GABA-A receptor; anion channel positive allosteric modulator
- Butabarbital sodium GABA-A receptor; anion channel positive allosteric modulator
- Butalbital GABA-A receptor; anion channel positive allosteric modulator
- Cenobamate GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide GABA-A receptor; anion channel positive allosteric modulator
- Chlordiazepoxide hydrochloride GABA-A receptor; anion channel positive allosteric modulator
- Cipepofol GABA-A receptor; anion channel agonist
- Clobazam GABA-A receptor; anion channel positive allosteric modulator
- Clomethiazole GABA-A receptor; anion channel positive allosteric modulator
- Clonazepam GABA-A receptor; anion channel positive allosteric modulator
- Clorazepate dipotassium GABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acid GABA-A receptor; anion channel positive allosteric modulator
- Clotiazepam GABA-A receptor; anion channel positive allosteric modulator
- Darigabat GABA-A receptor; anion channel agonist